GammaCan International, Inc. (GCAN.OB) Release: VitiGam(TM) Inhibits Melanoma Growth in a Dose Dependent Manner
8/11/2008 8:19:16 AM
More...
|
GammaCan International, Inc. (GCAN.OB) Executes Supply Agreement with Bio Products Laboratory to Manufacture VitiGam(TM) for the Treatment of Melanoma for Clinical Testing and Commercial Sale
6/4/2008 8:20:48 AM
More...
|
GammaCan International, Inc. (GCAN.OB) Announces Positive Testing Results in the Development of VitiGam(TM) for the Treatment of Melanoma
3/6/2008 11:34:24 AM
More...
|
GammaCan International, Inc. (GCAN.OB) to Present at the Rodman & Renshaw 9th Annual Healthcare Conference 2007
11/5/2007 9:46:32 AM
More...
|
GammaCan International, Inc. (GCAN.OB) Enters into Vitiligo Plasma Supply Agreement with DCI Biologicals
10/1/2007 9:45:23 AM
More...
|
Taglich Brothers Initiates Coverage on GammaCan International, Inc. (GCAN.OB)
9/21/2007 8:32:44 AM
More...
|
GammaCan International, Inc. (GCAN.OB) Receives FDA Orphan Drug Designation for Lead Product VitiGam(TM) for Stage IIB to Stage IV Melanoma
8/7/2007 1:05:31 PM
More...
|
GammaCan International, Inc. (GCAN.OB) Discovers Anti-Angiogenic Properties in Plasma-Derived IgG; Company Files Patent Application Pertaining to Disorders of Neovascularization Including Cancer and Other Diseases
6/28/2007 1:11:29 PM
More...
|
GammaCan International, Inc. (GCAN.OB) Retains Investor Relations Firm ROI Group
6/27/2007 1:31:33 PM
More...
|
GammaCan International, Inc. (GCAN.OB) to Present and Webcast at Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
5/14/2007 12:09:12 PM
More...
|
|